340B Program At ‘Critical Inflection Point,’ Oversight Agency Head Tells Providers

The head of the federal agency overseeing the 340B drug discount program offers unusually direct calls for legislative action during the safety net provider association winter conference. But is action likely in Congress any time soon?

pills on graph paper
• Source: Shutterstock

The US 340B drug discount program is at a “critical inflection point” that requires Congressional action to help assure it continues to serve the safety net provider community, Health Resources & Services Administration Office of Special Health Initiatives Director Krista Pedley told the 340B Health annual winter conference in San Diego on 30 January.

Pedley was unusually direct for an agency official in advocating for statutory changes to clarify program rules and HRSA’s authority...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access